FDA recently (Aug 12, 2013) approved
Tivicay (dolutegravir), a new antiretroviral agent for HIV-1
infection. Tivicay is approved to
treat HIV-infected adults who have never taken HIV therapy (treatment-naïve)
and HIV-infected adults who have previously taken HIV therapy
(treatment-experienced), including those who have been treated with other
integrase strand transfer inhibitors. Tivicay is also approved for children
ages 12 years and older weighing at least 40 kilograms (kg) who are
treatment-naïve or treatment-experienced but have not previously taken other
integrase strand transfer inhibitors. Dolutegravir is available as 50 mg
tablets. Dolutegravir is taken orally without regard to meals.
For complete information, click here
